Financials Qingdao Haier Biomedical Co.,Ltd

Equities

688139

CNE100003P25

Advanced Medical Equipment & Technology

End-of-day quote Shanghai S.E. 23:00:00 25/06/2024 BST 5-day change 1st Jan Change
39 CNY +6.21% Intraday chart for Qingdao Haier Biomedical Co.,Ltd +3.45% -3.75%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 9,157 20,702 28,796 20,078 12,824 12,312 - -
Enterprise Value (EV) 1 9,157 20,702 28,796 20,078 12,824 12,312 12,312 12,312
P/E ratio 39.6 x 54.4 x 34.1 x 33.5 x 31.7 x 22.2 x 17.9 x 14.6 x
Yield - - - - - - - -
Capitalization / Revenue 9.04 x 14.8 x 13.5 x 7.01 x 5.62 x 4.35 x 3.55 x 2.97 x
EV / Revenue 9.04 x 14.8 x 13.5 x 7.01 x 5.62 x 4.35 x 3.55 x 2.97 x
EV / EBITDA - 45.9 x 28.5 x 27.2 x 23.9 x 18.4 x 14.7 x 11.9 x
EV / FCF - - - - - - - -
FCF Yield - - - - - - - -
Price to Book - 7.46 x 8.01 x 5.01 x 3.05 x 2.65 x 2.35 x 2.07 x
Nbr of stocks (in thousands) 317,072 317,072 317,072 317,193 316,493 315,683 - -
Reference price 2 28.88 65.29 90.82 63.30 40.52 39.00 39.00 39.00
Announcement Date 26/03/20 22/02/21 16/02/22 27/02/23 26/02/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,013 1,402 2,126 2,864 2,281 2,829 3,465 4,150
EBITDA 1 - 450.7 1,011 738 536.8 670.9 839.6 1,030
EBIT 1 - 427.5 961.4 675.7 438.4 616.5 773.4 946.3
Operating Margin - 30.49% 45.23% 23.59% 19.22% 21.79% 22.32% 22.8%
Earnings before Tax (EBT) 1 - 424.2 960.9 675.3 434.5 615.2 771.7 944.6
Net income 1 - 381 845 600.8 406.1 558.3 694.9 847.4
Net margin - 27.17% 39.75% 20.98% 17.8% 19.73% 20.06% 20.42%
EPS 2 0.7300 1.200 2.660 1.890 1.280 1.757 2.183 2.667
Free Cash Flow - - - - - - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 26/03/20 22/02/21 16/02/22 27/02/23 26/02/24 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow - - - - - - - -
ROE (net income / shareholders' equity) - 14.6% 26% 15.9% 9.91% 11.9% 13.2% 14.2%
ROA (Net income/ Total Assets) - - - 11.6% 7.37% 8.8% 10.1% 11.1%
Assets 1 - - - 5,194 5,510 6,345 6,880 7,634
Book Value Per Share 2 - 8.750 11.30 12.60 13.30 14.70 16.60 18.80
Cash Flow per Share 2 - 2.200 1.870 1.990 0.7800 1.920 2.510 3.020
Capex 1 - - - 294 176 340 370 380
Capex / Sales - - - 10.27% 7.71% 12.02% 10.68% 9.16%
Announcement Date 26/03/20 22/02/21 16/02/22 27/02/23 26/02/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
39 CNY
Average target price
43 CNY
Spread / Average Target
+10.26%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 688139 Stock
  4. Financials Qingdao Haier Biomedical Co.,Ltd